Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Left Ventricular Dysfunction
100%
Genetic Model
100%
Empagliflozin
100%
Diastolic Function
33%
Left Ventricular Function
22%
Phospholamban
22%
SERCA2a
22%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
22%
Diabetes
11%
Insulin Sensitivity
11%
Blood Pressure
11%
Cardiovascular Mortality
11%
Cardiovascular Disease
11%
Histology
11%
Dysregulated
11%
Cardiac Function
11%
Phosphorylation
11%
Beneficial Effects
11%
High Mortality
11%
Echocardiography
11%
High Morbidity
11%
Signaling Pathway
11%
Hemoglobin A1c (HbA1c)
11%
Insulin Receptor Substrate 1 (IRS1)
11%
Cardiovascular Outcomes
11%
Heart Failure Hospitalization
11%
Insulin Level
11%
Chronic Treatment
11%
Contractile Reserve
11%
Molecular Profiling
11%
Glucose Utilization
11%
Weight Pressures
11%
New Antidiabetic Drugs
11%
Systolic Function
11%
Dobutamine
11%
Cardiac Relaxation
11%
Left Ventricular Systolic Function
11%
Reduced Body
11%
Glucose Control
11%
Hypoglycemia Risk
11%
Relaxation Function
11%
Steady-state Response
11%
Cardiac Phenotype
11%
In Vivo Hemodynamics
11%
Maximum Pressure
11%
Diastolic Dysfunction
11%
Calcium Handling
11%
Growth Signaling
11%
Myocardial Insulin Resistance
11%
Chronic Effects
11%
Clinical Utility
11%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Empagliflozin
100%
Left Ventricular Diastolic Dysfunction
100%
Diastolic Function
44%
Body Weight
22%
Systolic Function
22%
Phospholamban
22%
Ob/Ob Mouse
22%
Type 2 Diabetes
22%
Sodium-Glucose Cotransporter 2 Inhibitors
22%
Insulin Sensitivity
11%
Diabetes
11%
Blood Pressure
11%
Isotopes of Calcium
11%
Cardiovascular Disease
11%
Congestive Heart Failure
11%
Cardiovascular System
11%
Steady State
11%
Heart Function
11%
Dobutamine
11%
Hemodynamic
11%
Echocardiography
11%
Mitogen-Activated Protein Kinase
11%
Hemoglobin A1c
11%
Insulin Resistance
11%
Cardiovascular Mortality
11%
Hypoglycemia
11%
Molecular Profiling
11%
Glucose Utilization
11%
Diastolic Dysfunction
11%
Cell Signaling Pathway
11%
Protein Kinase B
11%
Pharmacology, Toxicology and Pharmaceutical Science
Empagliflozin
100%
Left Ventricular Diastolic Dysfunction
100%
Maturity Onset Diabetes of the Young
100%
Phospholamban
22%
Ob/Ob Mouse
22%
sodium glucose cotransporter-2 inhibitors
22%
Congestive Heart Failure
11%
Insulin Resistance
11%
Cardiovascular Mortality
11%
Hemoglobin A1c
11%
Hypoglycemia
11%
Diastolic Dysfunction
11%
Dobutamine
11%
Cardiovascular Disease
11%